vs
Side-by-side financial comparison of Foxx Development Holdings Inc. (FOXX) and Protalix BioTherapeutics, Inc. (PLX). Click either name above to swap in a different company.
Foxx Development Holdings Inc. is the larger business by last-quarter revenue ($16.7M vs $9.1M, roughly 1.8× Protalix BioTherapeutics, Inc.). Foxx Development Holdings Inc. runs the higher net margin — -25.6% vs -60.3%, a 34.7% gap on every dollar of revenue. On growth, Foxx Development Holdings Inc. posted the faster year-over-year revenue change (-4.4% vs -49.9%).
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.
FOXX vs PLX — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $16.7M | $9.1M |
| Net Profit | $-4.3M | $-5.5M |
| Gross Margin | 13.3% | 49.4% |
| Operating Margin | -13.3% | -51.1% |
| Net Margin | -25.6% | -60.3% |
| Revenue YoY | -4.4% | -49.9% |
| Net Profit YoY | -400.9% | -184.8% |
| EPS (diluted) | $-0.62 | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $16.7M | $9.1M | ||
| Q3 25 | $20.2M | $17.9M | ||
| Q2 25 | $13.9M | $15.7M | ||
| Q1 25 | $11.4M | $10.1M | ||
| Q4 24 | $17.5M | $18.2M | ||
| Q3 24 | $23.1M | $18.0M | ||
| Q2 24 | — | $13.5M | ||
| Q4 23 | — | $10.5M |
| Q4 25 | $-4.3M | $-5.5M | ||
| Q3 25 | $-2.9M | $2.4M | ||
| Q2 25 | $-4.1M | $164.0K | ||
| Q1 25 | $-4.1M | $-3.6M | ||
| Q4 24 | $1.4M | $6.5M | ||
| Q3 24 | $-2.3M | $3.2M | ||
| Q2 24 | — | $-2.2M | ||
| Q4 23 | — | $-6.0M |
| Q4 25 | 13.3% | 49.4% | ||
| Q3 25 | 13.6% | 53.4% | ||
| Q2 25 | 10.9% | 62.5% | ||
| Q1 25 | 5.8% | 19.1% | ||
| Q4 24 | 12.5% | 78.7% | ||
| Q3 24 | 1.7% | 53.4% | ||
| Q2 24 | — | 29.8% | ||
| Q4 23 | — | 15.5% |
| Q4 25 | -13.3% | -51.1% | ||
| Q3 25 | -4.4% | 11.9% | ||
| Q2 25 | -15.0% | 7.5% | ||
| Q1 25 | -31.3% | -41.0% | ||
| Q4 24 | -12.8% | 39.6% | ||
| Q3 24 | -7.8% | 22.2% | ||
| Q2 24 | — | -18.0% | ||
| Q4 23 | — | -53.5% |
| Q4 25 | -25.6% | -60.3% | ||
| Q3 25 | -14.2% | 13.2% | ||
| Q2 25 | -29.4% | 1.0% | ||
| Q1 25 | -35.9% | -35.8% | ||
| Q4 24 | 8.1% | 35.6% | ||
| Q3 24 | -9.8% | 18.0% | ||
| Q2 24 | — | -16.4% | ||
| Q4 23 | — | -57.6% |
| Q4 25 | $-0.62 | $-0.06 | ||
| Q3 25 | $-0.42 | $0.03 | ||
| Q2 25 | $-0.44 | $0.00 | ||
| Q1 25 | $-0.58 | $-0.05 | ||
| Q4 24 | $0.20 | $0.10 | ||
| Q3 24 | $-0.65 | $0.03 | ||
| Q2 24 | — | $-0.03 | ||
| Q4 23 | — | $-0.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.8M | $14.7M |
| Total DebtLower is stronger | $84.8K | — |
| Stockholders' EquityBook value | $-11.8M | $48.2M |
| Total Assets | $42.0M | $82.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.8M | $14.7M | ||
| Q3 25 | $1.5M | $13.6M | ||
| Q2 25 | $1.9M | $17.9M | ||
| Q1 25 | $3.8M | $19.5M | ||
| Q4 24 | $3.9M | $19.8M | ||
| Q3 24 | $9.2M | $27.4M | ||
| Q2 24 | — | $23.4M | ||
| Q4 23 | — | $23.6M |
| Q4 25 | $84.8K | — | ||
| Q3 25 | $90.2K | — | ||
| Q2 25 | $97.2K | — | ||
| Q1 25 | $100.5K | — | ||
| Q4 24 | $105.5K | — | ||
| Q3 24 | $110.3K | — | ||
| Q2 24 | — | — | ||
| Q4 23 | — | — |
| Q4 25 | $-11.8M | $48.2M | ||
| Q3 25 | $-7.9M | $52.9M | ||
| Q2 25 | $-5.4M | $49.9M | ||
| Q1 25 | $-1.6M | $45.2M | ||
| Q4 24 | $2.2M | $43.2M | ||
| Q3 24 | $457.2K | $32.4M | ||
| Q2 24 | — | $28.6M | ||
| Q4 23 | — | $33.6M |
| Q4 25 | $42.0M | $82.3M | ||
| Q3 25 | $49.8M | $82.3M | ||
| Q2 25 | $26.0M | $78.5M | ||
| Q1 25 | $32.9M | $73.9M | ||
| Q4 24 | $31.9M | $73.4M | ||
| Q3 24 | $49.5M | $61.6M | ||
| Q2 24 | — | $91.5M | ||
| Q4 23 | — | $84.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.05× | — | ||
| Q3 24 | 0.24× | — | ||
| Q2 24 | — | — | ||
| Q4 23 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $284.2K | $2.0M |
| Free Cash FlowOCF − Capex | — | $1.6M |
| FCF MarginFCF / Revenue | — | 17.8% |
| Capex IntensityCapex / Revenue | — | 4.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-13.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $284.2K | $2.0M | ||
| Q3 25 | $-376.8K | $-3.7M | ||
| Q2 25 | $-1.9M | $-5.2M | ||
| Q1 25 | $-178.4K | $-5.1M | ||
| Q4 24 | $-4.2M | $4.0M | ||
| Q3 24 | $-243.5K | $4.1M | ||
| Q2 24 | — | $-3.6M | ||
| Q4 23 | — | $3.6M |
| Q4 25 | — | $1.6M | ||
| Q3 25 | — | $-4.2M | ||
| Q2 25 | — | $-5.7M | ||
| Q1 25 | — | $-5.4M | ||
| Q4 24 | $-4.3M | $3.6M | ||
| Q3 24 | $-278.5K | $4.0M | ||
| Q2 24 | — | $-3.8M | ||
| Q4 23 | — | $3.3M |
| Q4 25 | — | 17.8% | ||
| Q3 25 | — | -23.7% | ||
| Q2 25 | — | -36.2% | ||
| Q1 25 | — | -53.0% | ||
| Q4 24 | -24.4% | 19.6% | ||
| Q3 24 | -1.2% | 22.4% | ||
| Q2 24 | — | -28.1% | ||
| Q4 23 | — | 31.9% |
| Q4 25 | — | 4.4% | ||
| Q3 25 | — | 2.8% | ||
| Q2 25 | 0.0% | 2.8% | ||
| Q1 25 | 0.0% | 3.0% | ||
| Q4 24 | 0.2% | 2.3% | ||
| Q3 24 | 0.2% | 0.5% | ||
| Q2 24 | — | 1.3% | ||
| Q4 23 | — | 2.4% |
| Q4 25 | — | — | ||
| Q3 25 | — | -1.58× | ||
| Q2 25 | — | -31.91× | ||
| Q1 25 | — | — | ||
| Q4 24 | -2.97× | 0.61× | ||
| Q3 24 | — | 1.27× | ||
| Q2 24 | — | — | ||
| Q4 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FOXX
Segment breakdown not available.
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
